Blog

Accutane Manufacturer Roche Cutting Jobs in U.S.

Although Roche Pharmaceuticals has denied liability in thousands of Accutane Lawsuits filed nationwide since it discontinued sales of the drug in June, 2009, the company is taking steps to prepare for hard times ahead.

Switzerland-based drug giant Roche announced today that it plans to reduce its worldwide job force by 6% over the next few years. This would mean a loss of approximately 6300 positions globally, with around 3550 of these coming from the United States.

The program, which was first hinted to in September, will attempt to save the company $2.4 billion by 2012. Most of the cuts will come from sales, marketing and commercial operations in the U.S. and Europe.

The company blames the decision largely on delays in the launch of its diabetes drug taspoglutide and losses from healthcare reform in the United States. It was recently announce the drug would be released 12 to 18 months later than expected. The recent healthcare changes are also expected to cost the company in upwards of $500 million annually.

Many Accutane attorneys also point to the fact that the drug maker faces thousands of lawsuits for alleged side effects from its popular Accutane drug which was sold between 1982 and 2009. Experts have linked the drug to serious bowel disorders such as Inflammatory Bowel Disease, Crohn’s Disease and Ulcerative Colitis. Check back with AccutaneRisks.com for more updates.